Non-Muscle Invasive Bladder Cancer Treatment Dilemmas: The Cases You Face and How Best to Treat Them Webcast (2025)
Overview
The course will highlight recent updates to AUA, European Association of Urology, and National Comprehensive Cancer Network Guidelines in the rapidly evolving field of bladder cancer before working through challenging but common case scenarios that will outline important changes as well as concepts essential in providing evidence-based care.
ACKNOWLEDGEMENTS:
This educational activity is supported by an independent educational grants from:
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Learning Objectives
At the conclusion of this activity, participants will be able to:
- Confidently apply updated guidelines to the care of patients with non-muscle-invasive bladder cancer.
- Risk-stratify patients with non muscle- invasive bladder cancer.
- Adapt treatment choices depending on risk of disease, including consideration to the availability of bacillus Calmette-Guérin.
- Counsel and manage patients with bacillus Calmette-Guérin-unresponsive non muscle-invasive bladder cancer, including treatment selection with newly approved agents for BCG-unresponsive disease.
- Individualize patient surveillance according to risk stratification.
- Evaluate available urinary bladder cancer biomarkers and where to potentially utilize them in practice to inform management.
Faculty
FACULTY DISCLOSURES
Name | Company Name | Relationship Type | End Date |
Anderson, Christopher | No relevant financial relationships to disclose | ||
McKiernan, James Michael | No relevant financial relationships to disclose | ||
Porten, Sima Prabodh | Photocure | Scientific Study or Trial | Current |
AstraZeneca | Consultant or Advisor | Current | |
Pacific Edge | Consultant or Advisor | Current | |
Ritch, Chad R. | Nonagen Inc | Consultant or Advisor | 01/01/2024 |
Ferring Inc | Consultant or Advisor | 12/04/2024 | |
Scarpato, Kristen R. | No relevant financial relationships to disclose |
EDUCATION COUNCIL DISCLOSURE
Education Council Disclosures_June 2024.pdf
COI REVIEW WORK GROUP DISCLOSURES
COI Review Workgroup Disclosures_June 2024.pdf
AUA Office of Education Staff has nothing to disclose.
All relevant financial relationships have been mitigated.
Accreditation
ACCREDITATION INFORMATION
Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
Release Date: May, 2025
Expiration Date: May, 2026
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.
Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
AUA PARTICIPANT INFORMATION & POLICIES
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
Available Credit
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation